Glucagon — An Important Therapeutic Agent

  • B. Chernow
Conference paper
Part of the Update in Intensive Care and Emergency Medicine book series (UICM, volume 1)


Endocrinology is finding an increasing role and importance in Critical Care and Emergency Medicine. Hormones clearly mediate much of the body’s homeostatic response to critical illness [5]. For example, catecholamines, aldosterone and anti-diuretic hormone are each released into the circulation during states of hypotension and shock. Endocrine and metabolic problems are common in critically ill patients. More than two-thirds of critically ill patients manifest abnormalities (at least biochemically) in either thyroid function [20], calcium metabolism [2, 21], or magnesium metabolism [19]. Hormones are also important therapeutic agents. Many hormones, peptides and receptor antagonists have been considered in the treatment of shock [6]. The purpose of this paper is to review the pharmacology and physiology of the hormone glucagon — as it applies to critical and emergency care.


Cardiogenic Shock Alcoholic Hepatitis Cardiovascular Action Endotoxin Shock Glucagon Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bower MG, Okude S, Jolley WB, et al (1970) Hemodynamic affects of glucagon–following hemorrhagic and endotoxic shock in the dog. Arch Surg 101: 411–415PubMedCrossRefGoogle Scholar
  2. 2.
    Chernow B, Zaloga GP, McFadden E, et al (1982) Hypocalcemia in critically ill patients. Crit Care Med 10: 848–851PubMedCrossRefGoogle Scholar
  3. 3.
    Chernow B, Reed C, MeyerhoffJ, Lake CR, Geelhoed G, Beardsley D, Holaday JW (1984) Verapamil antagonizes glucagon’s chronotropic effect. Circ Shock 13: 96–97Google Scholar
  4. 4.
    Chernow B, Clapper M, Malcolm D, Holaday JW (1976) Glucagon has a chronotropic effect on rats. Clin Res 32: 687AGoogle Scholar
  5. 5.
    Chernow B, Anderson DM (1985) Endocrine responses to critical illness. Seminar Respir Med 7 (1): 1–10CrossRefGoogle Scholar
  6. 6.
    Chernow B, Roth BL (1986) Pharmacologic support of the cardio-vasculature in septic shock. In: Sibbald WJ, Sprung CL (eds) Perspectives on Sepsis and Septic Shock, Society of Critical Care Medicine, Fullerton, pp 173–202Google Scholar
  7. 7.
    Deraney MF (1971) Glucagon? One answer to cardiogenic shock. Amer J Med Sci 261: 149154Google Scholar
  8. 8.
    Farah AE (1983) Glucagon and the circulation. Pharmacol Reviews 35: 181–217Google Scholar
  9. 9.
    Glick G, Parmley WW, Wechsler AS, Sonnenblick EH (1968) Glucagon–its enhancement of cardiac performance in the cat and dog and persistence of its inotropic action despite beta-receptor blockade with propranolol. Circulation Res 22: 789–799PubMedCrossRefGoogle Scholar
  10. 10.
    Guillen J, Pappas GL (1972) Improved cardiovasculalr effects of glucagon in dogs with endotoxin shock. Ann Surug 175: 535–538CrossRefGoogle Scholar
  11. 11.
    Hall-Boyer K, Zalogo GP, Chernow B (1984) Glucagon-hormone or therapeutic agent? Crit Care Med 12: 584–589PubMedCrossRefGoogle Scholar
  12. 12.
    Jain KM, Rush BR Jr, Hastings OM, et al (1978) Glucagon treatment of hemorrhagic shock. Adv Shock Res 1: 149–157PubMedGoogle Scholar
  13. 13.
    Lucchesi BR (1968) Cardiac actions of glucagon. Circ Res 22: 777–787PubMedCrossRefGoogle Scholar
  14. 14.
    Lvoff R, Wilcken DEL (1972) Glucagon in heart failure and in cardiogenic shock. Circulation 45: 534–542PubMedCrossRefGoogle Scholar
  15. 15.
    Parmley WW, Glick G, Sonnenblick EH 61968) Cardiovascular effects of glucagon in man. N Engl J Med 279: 12–17Google Scholar
  16. 16.
    Smith RC, Wilkinson J, Hull RL (1985) Glucagon for propranolol overdose. JAMA 254: 2412PubMedCrossRefGoogle Scholar
  17. 17.
    Teich S, Malcolm D, Holaday JW, Chernow B (1985) Beneficial effects of glucagon in endotoxin shock in rats. Circ Shock 16: 95Google Scholar
  18. 18.
    Unger RH, Eisentraut AM, McCall MS, et al (1959) Glucagon antibodies and their use for immunoassay for glucagon. Proc Soc Exp Biol Med 102: 621–623PubMedGoogle Scholar
  19. 19.
    Zaloga GP, Chernow B, Pock A, et al (1984) Hypomagnesemia is a common complication of aminoglycoside therapy. Surg Gynecol Obstet 158: 561–565PubMedGoogle Scholar
  20. 20.
    Zaloga GP, Chernow B, Smallridge RC, et al (1985) A longitudinal evaluation of thyroid function in critically ill surgical patients. Ann Surg 201: 456–464PubMedCrossRefGoogle Scholar
  21. 21.
    Zaloga GP, Chernow B, Cook D, et al (1985) Assessment of calcium homeostasis in the critically ill surgical patient. Ann Surg 202: 587–594PubMedCrossRefGoogle Scholar
  22. 22.
    Zaloga GP, Malcolm D, Holaday JW, Chernow B (1985B) Glucagon is a unique cardiovascular agent with anti-opiate activity. Crit Care Med 13: 273CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • B. Chernow

There are no affiliations available

Personalised recommendations